EVM
CRL icon

Eaton Vance Management’s Charles River Laboratories CRL Stock Holding History

Eaton Vance Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$2.29M Buy
11,658
+233
+2% +$50.3K ﹤0.01% 1017
2022
Q2 		$2.44M Sell
11,425
-831
-7% -$203K ﹤0.01% 1015
2022
Q1 		$3.48M Sell
12,256
-110,390
-90% -$34M ﹤0.01% 995
2021
Q4 		$46.2M Sell
122,646
-17,216
-12% -$6.69M 0.06% 316
2021
Q3 		$57.5M Buy
139,862
+15,088
+12% +$6.27M 0.08% 237
2021
Q2 		$46.2M Buy
124,774
+124,521
+49,218% +$41.6M 0.06% 291
2021
Q1 		$73K Buy
+253
New +$70.3K ﹤0.01% 1688
2014
Q2 		– Sell
-487,691
Closed -$29.4M – 889
2014
Q1 		$29.4M Buy
487,691
+30,538
+7% +$1.78M 0.09% 184
2013
Q4 		$24.2M Buy
457,153
+84,229
+23% +$4.23M 0.07% 200
2013
Q3 		$17.3M Buy
+372,924
New +$17.1M 0.05% 227

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Eaton Vance Management's CRL Position: Q3 2022 in Review

Eaton Vance Management increased its Charles River Laboratories (CRL) stake by 2% in Q3 2022, buying an estimated $50.3K and bringing the position to 11,658 shares worth $2.29M. The position accounts for ﹤0.01% of the portfolio, ranked #1017.

Eaton Vance Management first reported a position in CRL in Q3 2013 and has held it in 10 quarters since. The position peaked at $57.5M in Q3 2021. 582 funds tracked by Wall St. Rank hold CRL as of Q3 2022.

  • Eaton Vance Management held 11,658 shares of Charles River Laboratories worth $2.29M as of Q3 2022.
  • Eaton Vance Management bought 233 Charles River Laboratories shares in Q3 2022, an estimated $50.3K.
  • Charles River Laboratories made up ﹤0.01% of Eaton Vance Management's portfolio in Q3 2022, its #1017 holding.
  • Eaton Vance Management first reported a position in Charles River Laboratories in Q3 2013 and has held it in 10 quarters since.
  • Eaton Vance Management's Charles River Laboratories position peaked at $57.5M in Q3 2021.
  • 582 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2022.

Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.